NCT00657449View on ClinicalTrials.gov

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

PHASE4TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 4, 2003

Primary Completion Date

October 1, 2004

Study Completion Date

October 5, 2004

Conditions
Acute Pain
Interventions
DRUG

valdecoxib

valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8

DRUG

rofecoxib

rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days

Trial Locations (8)

90880480

Hospital Mãe de Deus, Porto Alegre

91350200

Grupo Hospitalar Conceiçao, Porto Alegre

74210-030

Instituto Ortopedico de Goiania, Goiânia

Unknown

Centro de Traumatologia e Ortopedia, Goiânia

Hospital Sao Zacarias, Rio de Janeiro

04822-320

Hospital Geral do Grajau, São Paulo

04063003

Unifesp - Hsp, São Paulo

05001000

SECONCI, São Paulo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00657449 - A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain | Biotech Hunter | Biotech Hunter